Literature DB >> 18321680

Electrophysiological basis for the ability of olanzapine to improve verbal memory and functional outcome in patients with schizophrenia: a LORETA analysis of P300.

Yuko Higuchi1, Tomiki Sumiyoshi, Yasuhiro Kawasaki, Mie Matsui, Hirofumi Arai, Masayoshi Kurachi.   

Abstract

Abnormality of P300 waveforms of event-related potentials (ERPs) has been suggested to represent an aspect of the pathophysiology of schizophrenia. Previous work points to the contribution of altered neural function in discrete brain regions in the left hemisphere to psychotic symptoms and cognitive deficits of schizophrenia. In this study, we sought to determine: 1) if patients with schizophrenia elicit a decreased P300 current source density in brain areas, such as the superior temporal gyrus (STG); 2) if decreased P300 generator density in the left STG is recovered by treatment with the most widely-used antipsychotic drug olanzapine; and 3) if the recovery of P300 source density is associated with improvements of cognitive and functional status. P300 in response to an auditory oddball task, as well as verbal learning memory, psychopathology, and quality of life were evaluated in 16 right-handed patients with schizophrenia before and after treatment with olanzapine for 6 months. ERP data were also obtained from 16 right-handed age and gender-matched normal volunteers. Low resolution electromagnetic tomography (LORETA) analysis was used to obtain current density images of P300. Patients with schizophrenia showed significantly smaller LORETA values in several brain regions in the left side, particularly STG, middle frontal gyrus, and precentral gyrus, compared with control subjects. Six-month treatment with olanzapine significantly increased P300 source density only in the left STG. Positive symptoms, negative symptoms, verbal learning memory, and quality of life were also improved during treatment. Significant correlations were found between the increase in LORETA values of left STG vs. improvements of negative symptoms, as measured by Scale for the Assessment of the Negative Symptoms, and verbal learning memory, as measured by the Japanese Verbal Learning Test. Improvement of quality of life, as evaluated by the Quality of Life Scale, were significantly associated with an increase in LORETA values of middle frontal gyrus, and tended to correlate with that of precentral gyrus. The results of this study suggest that changes in cortical activity, as measured by ERPs, are responsible for the ability of some antipsychotic drugs to improve cognition and functional outcome in patients with schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18321680     DOI: 10.1016/j.schres.2008.01.020

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  11 in total

Review 1.  Does neuroimaging research examining the pathophysiology of posttraumatic stress disorder require medication-free patients?

Authors:  Ruth A Lanius; Chris R Brewin; J Douglas Bremner; Judith K Daniels; Matthew J Friedman; Israel Liberzon; Alexander McFarlane; Paula P Schnurr; Lisa Shin; Murray Stein; Eric Vermetten
Journal:  J Psychiatry Neurosci       Date:  2010-03       Impact factor: 6.186

2.  Prolonged P300 Latency in Antipsychotic-Free Subjects with At-Risk Mental States Who Later Developed Schizophrenia.

Authors:  Yuko Higuchi; Tomiki Sumiyoshi; Takahiro Tateno; Suguru Nakajima; Daiki Sasabayashi; Shimako Nishiyama; Yuko Mizukami; Tsutomu Takahashi; Michio Suzuki
Journal:  J Pers Med       Date:  2021-04-21

Review 3.  Electrophysiological and neuropsychological predictors of conversion to schizophrenia in at-risk subjects.

Authors:  Tomiki Sumiyoshi; Tomohiro Miyanishi; Tomonori Seo; Yuko Higuchi
Journal:  Front Behav Neurosci       Date:  2013-10-21       Impact factor: 3.558

4.  Mismatch negativity and p3a/reorienting complex in subjects with schizophrenia or at-risk mental state.

Authors:  Yuko Higuchi; Tomonori Seo; Tomohiro Miyanishi; Yasuhiro Kawasaki; Michio Suzuki; Tomiki Sumiyoshi
Journal:  Front Behav Neurosci       Date:  2014-05-13       Impact factor: 3.558

Review 5.  Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy.

Authors:  Mark J Millan; Yves Agid; Martin Brüne; Edward T Bullmore; Cameron S Carter; Nicola S Clayton; Richard Connor; Sabrina Davis; Bill Deakin; Robert J DeRubeis; Bruno Dubois; Mark A Geyer; Guy M Goodwin; Philip Gorwood; Thérèse M Jay; Marian Joëls; Isabelle M Mansuy; Andreas Meyer-Lindenberg; Declan Murphy; Edmund Rolls; Bernd Saletu; Michael Spedding; John Sweeney; Miles Whittington; Larry J Young
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

6.  LORETA current source density for duration mismatch negativity and neuropsychological assessment in early schizophrenia.

Authors:  Tomohiro Miyanishi; Tomiki Sumiyoshi; Yuko Higuchi; Tomonori Seo; Michio Suzuki
Journal:  PLoS One       Date:  2013-04-05       Impact factor: 3.240

7.  Mismatch negativity and cognitive performance for the prediction of psychosis in subjects with at-risk mental state.

Authors:  Yuko Higuchi; Tomiki Sumiyoshi; Tomonori Seo; Tomohiro Miyanishi; Yasuhiro Kawasaki; Michio Suzuki
Journal:  PLoS One       Date:  2013-01-17       Impact factor: 3.240

Review 8.  Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia.

Authors:  Tomiki Sumiyoshi; Yuko Higuchi; Takashi Uehara
Journal:  Front Behav Neurosci       Date:  2013-10-16       Impact factor: 3.558

9.  P300 aberration in first-episode schizophrenia patients: a meta-analysis.

Authors:  Yao-qin Qiu; Yun-xiang Tang; Raymond C K Chan; Xin-yang Sun; Jia He
Journal:  PLoS One       Date:  2014-06-16       Impact factor: 3.240

10.  Neural substrate of quality of life in patients with schizophrenia: a magnetisation transfer imaging study.

Authors:  Catherine Faget-Agius; Faget-Agius Catherine; Laurent Boyer; Jonathan Wirsich; Wirsich Jonathan; Jean-Philippe Ranjeva; Ranjeva Jean-Philippe; Raphaelle Richieri; Richieri Raphaelle; Elisabeth Soulier; Soulier Elisabeth; Sylviane Confort-Gouny; Confort-Gouny Sylviane; Pascal Auquier; Auquier Pascal; Maxime Guye; Guye Maxime; Christophe Lançon; Lançon Christophe
Journal:  Sci Rep       Date:  2015-12-03       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.